Terezepitide
Sources:
Terzepatide, known by the brand names like Munjaro for diabetes and Zepbound for obesity, is a promising weight loss medication that discusses on the . It acts as a dual agonist targeting both the GLP-1 receptor and the GIP receptor, unlike other GLP-1 receptor agonists like Ozempic, which only target one receptor. This dual action not only enhances weight loss but also reduces nausea, a common side effect of GLP-1 agonists. Clinical trials have shown significant weight loss, with some users experiencing up to 25% body weight reduction, results comparable to bariatric surgery 1.
Terzepatide's efficacy in weight loss is slightly higher than other alternatives, thanks to its dual receptor activity. However, one concern is that while users may experience significant weight loss, they often lose both fat and muscle equally, which raises questions about long-term health impacts, like muscle loss (sarcopenia) that could influence mortality risks 2. Some have explored combining terzepatide with compounds like semirelin in compounding pharmacies to mitigate muscle loss by stimulating growth hormone release 3.
RELATED QUESTIONS
